KBC Split
- Address
- lock Available on a paid plan
Severe Alopecia Areata
The Dermatology Department at KBC Split is conducting studies that test the effectiveness and safety of a novel oral therapy for patients with severe alopecia areata, including both adults and adolescents.
- Assessing rapid regrowth of hair using clinical scoring tools
- Evaluating long‑term safety and tolerability of the treatment
- Optimizing dosing strategies based on patient response
These trials aim to provide new therapeutic options for an autoimmune disease that currently has limited treatments, leveraging the expertise of 28 investigators across five active studies.
Active Lupus Nephritis
Researchers at KBC Split are exploring a targeted agent for patients with active lupus nephritis, a serious manifestation of immune system diseases.
- Investigating proteasome inhibition as a novel mechanism
- Monitoring renal function and disease activity during treatment
- Assessing safety in patients with class III/IV and pure class V disease
The goal is to expand therapeutic options for complex autoimmune conditions, complementing the site’s broader focus on immune‑mediated disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 17 therapeutic areas and 15 of 106 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 106 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 18 by active trials.
lock +17 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG17trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in KBC Split
lock Showing 1 of 65 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Pharmacokinetic and Safety Study of Bimekizumab via Different Routes of Administration in Adults with Chronic Cutaneous Inflammation | UCB Biopharma | Phase I | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 106 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Upadacitinib | 8 | Unknown | 2016-05-10 | 2024-06-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.